FLT3 and acute myeloid leukemia: These results support those reported by Schlenk and colleagues, showing an improved event-free survival (EFS) and OS in patients with FLT3-ITD-positive AML starting maintenance therapy with midostaurin within 100 days post-transplant compared to patients having received midostaurin in induction and consolidation only (24).